Press releases
US-specific press releases are available here. Please visit our global website for access to global press releases dating back to 2009.
-
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV
ViiV Healthcare submits regulatory application to European Medicines Agency
Read more -
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance
ViiV Healthcare presents GEMINI 1 & 2 studies
Read more -
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
Data from the TANGO study presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019)
Read more -
GSK delivers sales and earnings growth in Q2 2019
Total EPS 19.5p, +>100% AER, +>100% CER; Adjusted EPS 30.5p +9% AER, +4% CER
Read more -
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
Read more -
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
Week 96 data from BRIGHTE study of first-in-class fostemsavir continue to show improvement in virologic suppression and immunologic response
Read more -
GSK ships 2019-20 seasonal influenza vaccines for US market
GSK today announced it will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2019-20 flu season, immediately following licens...
Read more -
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
Data presented challenging the current treatment paradigm, investigating new options to meet the evolving needs of people living with HIV
Read more -
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
Niraparib demonstrates significant improvement in progression free survival for women regardless of their biomarker status
Read more -
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with the 2-drug regimen Dovato (dolutegravir plus lamivudine) in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
Read more -
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019
Read more -
GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
First phase III program in RA to include head-to-head comparisons with current treatments across all pivotal studies in a broad range of difficult-to-treat RA patients
Read more -
GSK joins forces with the University of California to advance genomic research and improve drug discovery
New ‘Laboratory for Genomics Research’ unites CRISPR pioneers with industry expertise to help unravel mysteries of the human genome
Read more -
Nucala (mepolizumab) gains FDA approval for two new self-administration options
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinject...
Read more -
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
Read more -
Save the Children Announces $1.5 Million Grant from GSK to Enhance Disaster Relief
GSK will donate $1.5 million over three years to help enhance the global nonprofit’s ability to respond to disasters in the United States.
Read more -
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster)...
Read more -
GSK changes sales representative incentive program
We are announcing changes to our incentive program for sales representatives in certain countries.
Read more -
GSK’s strong science prominent at ATS 2019
GlaxoSmithKline plc (LSE/NYSE: GSK) will present more than 70 abstracts at the American Thoracic Society (ATS) International Conference 17-22 May, Dallas, US
Read more -
GSK Science in the Summer™ Aims to Inspire Youth with STEM Learning through the ‘Science of Me’
Science in the Summer kicks off registration on May 13 and promises a one-of-a-kind science experience.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
